BioMed Nexus

Add social links

Amgen Took the Mic and Said Nothing. We Grade the Silence.

Amgen named no dates at Morgan Stanley, Scholar Rock's price came out two ways, the FDA approved the first Lutathera equivalent, and Monday's readout winners gave it back.

The FDA Showed Up Early. Amgen Still Hasn't.

The FDA approved Scholar Rock's Isembyld 19 days before its action date, AstraZeneca printed a PFS win beside a survival question at WCLC, two B7-H3 ADCs posted the same hazard ratio, and Definium went three for three in anxiety.

The Approval Held. The Franchise Didn't.

AstraZeneca's SERENA-4 missed eight days after Etcamah's approval, WCLC put an 18.5 month small cell survival number on the board, SK put dates and conditions on the Biohaven close, and two long open items resolved on primary documents.

The Discount Reached the Boardroom

The FDA paused Biohaven's pivotal epilepsy enrollment fifteen days after its up to $795M SK deal, an Artisan Partners manager demanded Novartis board changes, Axogen paid $200M for sutureless nerve repair, and the surrogate discount week closed with nothing round tripped.

Three Toplines, Zero Numbers

BMS' arlo-cel cleared its pivotal myeloma trial with the data held for a congress, Bayer's Hyrnuo won first line lung cancer approval on a 75% response rate, the FDA's drug and biologics chiefs went permanent, and three private rounds raised $550 million in a day.

Amgen Paid for Novartis' Miss

Del-desiran failed its Phase 3 with the numbers withheld, Amgen dropped 10.1% on Lp(a) readacross despite an Imdelltra survival win, the FDA approved Etcamah over its advisers' no vote, and Boston Scientific told the SEC its guidance is out of reach.

The Number Went Down. The Risk Didn't.

Pelacarsen and ziltivekimab failed outcomes tests four days apart, semaglutide moved 40.4% of children out of obesity, and Menarini priced ledger entry #14 at exactly 8.5%. Plus Boston Scientific's recall and recovery, and the week's through line.

The Bispecific That Beat Keytruda

Ivonescimab cleared the survival bar against pembrolizumab in China and kept the numbers, Ultragenyx's Angelman Phase 3 failed, and GSK paid $110M upfront for a preclinical KRAS conjugate. Plus the week's delivered catalyst tally: 1 of 13.

The Ex Vivo Exit Queue

TScan cut 75% and listed its autoimmune program, Novartis paid up to $3.2B for Alteogen's delivery enzyme, and uniQure filed the first Huntington's gene therapy BLA. Plus the Medicare GLP-1 numbers and Teva's celiac win.

The Day Autoimmune CAR T Hit the Wall

Novartis and BMS paused their autoimmune CAR T programs after patient deaths while Roche paid $75M upfront for Simcere's B cell trispecific. Plus REMODEL's clean liver, the Alumis lupus wipeout, and GSK's mRNA flu Phase 3.

The MFN Deal Came, the Biotechs Didn't

Nine drugmakers joined the White House pricing program and none of them was the midsize biotech the story was about. Plus Lilly's up to $2.875B Merida buy, BioMarin's 20% royalty, and Monday's delivered catalyst tally.

Five Catalysts Delivered, Five Stocks Down

The FDA's queue delivered Mimrylo and Lisraya, Mounjaro got a non inferiority heart label, and ESC repriced numbers the market already had.

Four Dates, Zero Decisions

The empty date week ends in a ratio: Boston Scientific's cyberattack, Tezspire's numberless Phase 3 win, and the only actors who beat their clocks.

The FDA Showed Up Early

The first broad RAS drug in pancreatic cancer arrived ahead of schedule. Plus Ziihera's seven month survival gain, Biohaven's $795M exit, and the question we said we would ask.

The $1.5B Deal That Skipped the IPO Window

ARCH and Population Health launch Sentivera around a preclinical Haisco asset. Plus the IPO window nears escape velocity, Foundayo lands in the UK, and the empty date tally holds at zero.

The Empty Date Filled In With Another Date

Capricor's PDUFA moves to November 22 with a refined upper limb ask. Plus Roche's $2.3B Hanmi bet, REGENXBIO's clinical hold, and the FDA's TEMPO pilot goes behavioral.

The PDUFA Date That Produced Nothing

Capricor's Saturday deadline passed unanswered, Xspray's third factory rejection, and what a Nasdaq listing costs in 2026.

The Ledger Tally: Amylyx Priced $500M at the Top of Its Tape

An upsized raise with no discount, two rare disease approvals in a day, and the full seven column count.

The Cancer Vaccine Won Its Phase 3, and Amylyx Went to the Wire

Merck and Moderna's intismeran autogene met both melanoma endpoints with no numbers disclosed. Plus Amylyx's $350 million raise, the Overton nomination made official, and Teva's partial IRA win.

A Name for the FDA, and Amylyx's 55% Win

Trump is expected to nominate Heidi Overton. Plus BioMarin's $275 million Alesta deal, LEO's $435 million dersimelagon buy, and a third death in China's opaque trials.

EyePoint's Eylea Challenger Missed by Nine Patients

AstraZeneca dropped one lung cancer Phase 3 and won two. Plus Slate's $245 million reverse merger and Lilly's ion channel bet.

The FDA Just Postponed Capricor's Coin Flip

Deramiocel's August 22 date is set to move, the Celgene CVR suit is back, and we open the week's binary ledger.

A Gene Editing Pioneer Just Sold for Parts

Lilly took the platforms, PTC took the drug, and the week's argument got its price. Plus the first CELMoD approval.

The LSD Pill Is Two for Two in Phase 3

Definium's DT120 held a three month effect in anxiety from one dose. Plus a hard day for Prader-Willi.

The FDA Rejected the Factory, Not the Drug

ITM's CRL and Scholar Rock's filing rework share one failure category: manufacturing.